Arcutis Biotherapeutics, Inc.

NasdaqGS ARQT

Arcutis Biotherapeutics, Inc. Net Cash Used Provided By Financing Activities for the Trailing 12 Months (TTM) ending September 30, 2024: USD 262.90 M

Arcutis Biotherapeutics, Inc. Net Cash Used Provided By Financing Activities is USD 262.90 M for the Trailing 12 Months (TTM) ending September 30, 2024, a 8,675.10% change year over year. Net cash used/provided by financing activities are the total cash inflows and outflows related to activities that finance the company’s operations, including debt, equity, and dividends.

Arcutis Biotherapeutics, Inc. Net Cash Used Provided By Financing Activities for the Trailing 12 Months (TTM) ending September 30, 2023 was USD 3.00 M, a -99.20% change year over year.
Arcutis Biotherapeutics, Inc. Net Cash Used Provided By Financing Activities for the Trailing 12 Months (TTM) ending September 30, 2022 was USD 373.72 M, a 10.42% change year over year.
Arcutis Biotherapeutics, Inc. Net Cash Used Provided By Financing Activities for the Trailing 12 Months (TTM) ending September 30, 2021 was USD 338.45 M, a 29.32% change year over year.
Arcutis Biotherapeutics, Inc. Net Cash Used Provided By Financing Activities for the Trailing 12 Months (TTM) ending September 30, 2020 was USD 261.72 M.

Key data

Date	Net Cash Used Provided By Financing Activities	Dividends Paid	Capital Expenditure	Effect Of Forex Changes On Cash

NasdaqGS: ARQT

Arcutis Biotherapeutics, Inc.

CEO	Mr. Todd Franklin Watanabe M.A.
IPO Date	Jan. 31, 2020
Location	United States
Headquarters	3027 Townsgate Road
Employees	296
Sector	Healthcare
Industries Pharmaceuticals Augmented Reality (AR) Biotechnology Clinical Trials Cosmetics Drugstores & Retail Pharmacies Eyewear Personal Care

Description

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical foam formulation of roflumilast for the treatment of seborrheic dermatitis and scalp psoriasis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; and ARQ-255, a topical formulation of ARQ-252 designed to reach deeper into the skin in order to treat alopecia areata. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.

Key trends

Past 5 years